How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,769 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Papular Mycosis Fungoides is a Distinctive Variant of Early-stage Mycosis Fungoides: Extended Retrospective Study With Long-term Follow-up. (Abstract)

Papular Mycosis Fungoides is a Distinctive Variant of Early-stage Mycosis Fungoides: Extended Retrospective Study With Long-term Follow-up. Papular mycosis fungoides (PMF) is a rare variant of mycosis fungoides (MF). The exact nosology and prognosis of PMF are still unclear. We retrospectively identified cases of PMF from the files of the Department of Dermatology of the Medical University of Graz, Austria, and checked the follow-up data. The patients comprised 13 men and 5 women (median age

2019 American Journal of Surgical Pathology

3. Chlormethine (Ledaga) - mycosis fungoides-type cutaneous T-cell lymphoma

Chlormethine (Ledaga) - mycosis fungoides-type cutaneous T-cell lymphoma 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/CHMP/13156/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) purified HPRT hypoxanthine-guanine phosphoribosyltransferase IARC International Agency for Research on Cancer IC50 half-maximal inhibitory concentration ICH International Conference on Harmonisation IID Inactive Ingredient Database i.p. intraperitoneal i.v. intravenous IR InfraredKF Karl Fischer titration LD50 median lethal dose MDA malondialdehyde MDEA N-methyldiethanolamine MF mycosis fungoides MF-type CTC mycosis fungoides-type cutaneous T-cell lymphoma MNNG N-methyl-N´-nitro-N-nitrosoguanidine MTD

2017 European Medicines Agency - EPARs

4. Corneal infiltration and xanthoma formation in mycosis fungoides Full Text available with Trip Pro

Corneal infiltration and xanthoma formation in mycosis fungoides To report a case of corneal infiltration and xanthoma formation in mycosis fungoides (cutaneous T-cell lymphoma).A middle aged Japanese man with mycosis fungoides (MF) involving the face was referred to Ophthalmology for evaluation of unilateral, painless conjunctival injection. Biopsy of the conjunctiva revealed a malignant T cell population consistent with MF tumor invasion. Years later, he returned following several episodes

2018 American journal of ophthalmology case reports

5. Large-Cell Transformed Mycosis Fungoides Coexisting with Mycosis Fungoides Bullosa: A Case Report and Review of the Literature Full Text available with Trip Pro

Large-Cell Transformed Mycosis Fungoides Coexisting with Mycosis Fungoides Bullosa: A Case Report and Review of the Literature Mycosis fungoides is the most common form of cutaneous T-cell lymphoma. Both large-cell transformed mycosis fungoides and mycosis fungoides bullosa are rare presentations and predict unfavorable prognosis. We report the case of a 61-year-old woman who presented with generalized erythematous scaly annular plaques, and histopathology confirmed the diagnosis of mycosis (...) ). One day after receiving chemotherapy, multiple tense bullae on normal-appearing skin and mycosis fungoid plaques erupted. A histological study demonstrated subepidermal blistering with epidermotropism of atypical lymphocytes. Direct immunofluorescence study was negative. The results confirmed the diagnosis of mycosis fungoides bullosa. We present the first reported case of large-cell transformed mycosis fungoides coexisting with mycosis fungoides bullosa.

2017 Case reports in dermatology

6. Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness

Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness Published on: September 30, 2015 Project (...) Number: RB0915-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of extracorporeal photopheresis (ECP) for the management of Sezary Syndrome or Mycosis fungoides? What is the cost-effectiveness of ECP for the management of Sezary Syndrome or Mycosis fungoides? Key Message One systematic review, four non-randomized studies, and one economic evaluation were identified regarding extracorporeal

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®): Health Professional Version

Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®): Health Professional Version Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ (...) Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002-. Search term Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) Health Professional Version PDQ Adult Treatment Editorial Board . Published online: September 20, 2019. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of mycosis fungoides (including Sézary Syndrome). It is intended as a resource to inform and assist clinicians who

2018 PDQ - NCI's Comprehensive Cancer Database

8. Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis Full Text available with Trip Pro

Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis Mycosis fungoides (MF) is a significant diagnostic challenge; it has various differential diagnosis especially at an early stage. Our aim was to describe mimics of MF clinically and histologically, and to define significant diagnostic criteria of the disease.This was a retro-prospective cohort of 370 patients in whom the diagnosis of MF was suspected clinically.MF was histologically

2017 International journal of women's dermatology

9. Mycosis fungoides progression could be regulated by microRNAs. Full Text available with Trip Pro

Mycosis fungoides progression could be regulated by microRNAs. Differentiating early mycosis fungoides (MF) from inflammatory dermatitis is a challenge. We compare the differential expression profile of early-stage MF samples and benign inflammatory dermatoses using microRNA (miRNA) arrays. 114 miRNAs were found to be dysregulated between these entities. The seven most differentially expressed miRNAs between these two conditions were further analyzed using RT-PCR in two series comprising 38

2018 PLoS ONE

10. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. (Abstract)

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS).CITN-10 is a single-arm, multicenter phase II trial of 24 patients with advanced MF or SS. Patients were treated with pembrolizumab 2 mg/kg every 3 weeks for up to 24 months. The primary end point was overall response rate by consensus global response

2019 Journal of Clinical Oncology

11. Bexarotene as maintenance treatment after other than skin-directed therapy in advanced stage mycosis fungoides: a pilot study. (Abstract)

Bexarotene as maintenance treatment after other than skin-directed therapy in advanced stage mycosis fungoides: a pilot study. Advanced-stage mycosis fungoides (MF) and Sézary Syndrome (SS) patients have a poor quality of life and quickly relapse irrespective of the administered treatment. Most of the available therapies do not warrant long-lasting remission. In the last ten years, the need for an MF maintenance treatment has been investigated in the literature, with most of experiences

2019 Journal of the European Academy of Dermatology and Venereology

12. Epidemiological, clinical, histological, and immunohistochemical study on hypopigmented epitheliotropic T-cell dyscrasia and hypopigmented mycosis fungoides. (Abstract)

Epidemiological, clinical, histological, and immunohistochemical study on hypopigmented epitheliotropic T-cell dyscrasia and hypopigmented mycosis fungoides. Hypopigmented dermatoses, more evident in dark-skinned people, are a frequent cause of consultation. Their etiology includes a wide range of dermatoses, from benign to malignant diseases. The clinical presentation appears very similar between them, making the correct diagnoses and management a challenge.Clinical records (...) and histopathological biopsies were identified and compared in patients of the "Dr. Manuel Gea González" General Hospital throughout a 16-year period with the presumptive diagnosis of hypopigmented epitheliotropic T-cell dyscrasia (HTCD) or hypopigmented mycosis fungoides (HMF). Immunostaining analysis was performed in each specimen, the panel of antibodies used was: CD3, CD4, CD7, CD8, CD20, and CD62L.Thirty cases of 81 patients found in the registries were included in this study. The main age group was formed

2019 International Journal of Dermatology

13. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Full Text available with Trip Pro

Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Cutaneous T-cell lymphomas (CTCL) are a heterogenous group of T-cell neoplasms involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).The diagnosis of MF or SS requires the integration of clinical and histopathologic data.TNMB (tumor, node, metastasis, blood) staging remains the most important prognostic factor in MF/SS and forms the basis

2019 American journal of hematology

14. Regression of Mycosis Fungoides with Large Cell Transformation Following Skin Biopsy. (Abstract)

Regression of Mycosis Fungoides with Large Cell Transformation Following Skin Biopsy. Cutaneous T-cell lymphomas (CTCLs) are a group of mature extranodal T-cell lymphomas, of which mycosis fungoides (MF) is the most common subtype. MF commonly presents as patch-or-plaques on non-sun exposed areas of the body and often follows an indolent clinical course (1). Advanced MF, stage IIb-IV, has a 5-year survival which ranges from 28 to 68%. (2) Large cell transformation (LCT), age greater than 60

2019 Journal of the European Academy of Dermatology and Venereology

15. Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression. (Abstract)

Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression. Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma1 . The clinical course is usually slow and the initial treatment is a skin-directed therapy2,3 . When MF becomes refractory, systemic therapies are needed2,3 . Disease progression is seen in about 30% of MF patients but no undisputable markers are available to identify these patients2,3 . Twist, Zeb1 and Slug are transcription

2019 Journal of the European Academy of Dermatology and Venereology

16. Exploratory Assessment Of Oxygen Flow Assisted Cutaneous Administration Of Methotrexate For Superficial Basal Cell Carcinoma, Mycosis Fungoides And Extramammary Paget's Disease. (Abstract)

Exploratory Assessment Of Oxygen Flow Assisted Cutaneous Administration Of Methotrexate For Superficial Basal Cell Carcinoma, Mycosis Fungoides And Extramammary Paget's Disease. The molecular weight of methotrexate (MTX) makes cutaneous penetration difficult. Oxygen flow could enhance the skin permeation of MTX diluted in the LP3 carrier system. This pilot study aims to assess the efficacy, safety and tolerance of oxygen-flow-administered (OFA)-LP3-MTX3% for treating superficial skin cancers (...) . Patients with superficial basal cell carcinoma (sBCC)(n=12), extramammary Paget's disease (EMPD)(n=5), mycosis fungoides classic type (CMF) (n=10) and folliculotropic (FMF) (n=6) were included in the study and were treated with 4 weekly applications of OFA-LP3-MTX3%. Photographs and biopsies were performed before (T0) and one month after treatment (T1). At T1, the mean sBCC ECT and EMPD EOSP clinical scores, and the modified CAILS CMF and FMF scores were improved by 77.5±17.1% (p<0.0001), 66.7±22.9% (p

2019 Journal of Investigative Dermatology

17. Outcomes and Prognostic Factors In African American / Black Patients With Mycosis Fungoides And Sézary Syndrome: Retrospective Analysis Of 157 Patients From A Referral Cancer Center. (Abstract)

Outcomes and Prognostic Factors In African American / Black Patients With Mycosis Fungoides And Sézary Syndrome: Retrospective Analysis Of 157 Patients From A Referral Cancer Center. The prevalence of mycosis fungoides / Sézary syndrome (MF/SS) is higher in the African American (AA)/black population compared to Caucasians in the United States and worse outcomes have been observed in AA/black patients.To describe the outcomes and to identify prognostic factors in AA/black patients with MF

2019 Journal of American Academy of Dermatology

18. SHARPIN overexpression promotes TAK1 expression and activates JNKs and NF-κB pathway in Mycosis Fungoides. (Abstract)

SHARPIN overexpression promotes TAK1 expression and activates JNKs and NF-κB pathway in Mycosis Fungoides. Mycosis Fungoides (MF) is the most common subtype of cutaneous T-cell lymphomas (CTCL). Shank-associated RH domain-interacting protein (SHARPIN) participates in the initiation and development of multiple tumors. However, the clinical significance of SHARPIN in MF hasn't been investigated. The c-Jun N-terminal kinases (JNKs) pathway is a member of mitogen-activated protein kinases (MAPKs

2019 Experimental Dermatology

19. Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: a randomized controlled trial. (Abstract)

Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: a randomized controlled trial. Background: Mycosis fungoides is the most common type of primary cutaneous T cell lymphomas. Doxycycline promoted apoptosis in different human malignant cell lines and in vivo models. Objectives: To test for the therapeutic efficacy of doxycycline in comparison to PUVA in early stages of classic MF and its effect on T cell apoptosis. Methods: Thirty-six patients were randomized

2019 Journal of Dermatological Treatment

20. Poikilodermatous Mycosis Fungoides: Comparative Study of Clinical, Histopathological and Immunohistochemical Features. (Abstract)

Poikilodermatous Mycosis Fungoides: Comparative Study of Clinical, Histopathological and Immunohistochemical Features. Poikilodermatous mycosis fungoides (pMF) is characterized by poikiloderma areas, typically involving the major flexural areas and trunk. Its presentation can be generalized or admixed with other forms of MF. Previous studies fail to correlate the clinical presentation with prognosis and laboratory findings. Some reports show pityriasis lichenoides chronica (PLC) preceding

2019 Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>